Poster Program

Poster Session 1
Sunday 2 October, 18:00 – 20:00

Clinical trials	
[P1.1.1]	**Clinical performance of a novel intradermal injection device** C. Jarrahian*, E. Saxon, E. Griswold, D. Zehrung, *PATH, USA*
[P1.1.2]	**A randomized, double-blind, placebo-controlled trial to evaluate a Live, attenuated Vietnamese rotavirus vaccine (Rotavin-M1) in infants** N.V. Trang*[1], D.D. Anh[1], V.D. Thiem[1], N.T.H. Anh[1], N.D. Mao[2], N.V. Thom[3], N.V. Diu[3], N.D. Hien[4], L.T. Luan[4], *[1]The National Institute of Hygiene and Epidemiology, Viet Nam, [2]Center of Preventive Medicine Phu Tho province, Viet Nam, [3]Center of Preventive Medicine Thai Binh province, Viet Nam, [4]Center for Research and Development of Vaccines and Biologicals, Viet Nam*
Human vaccines, infectious diseases (bacteria)	
[P1.2.1]	**Progress and setbacks in the search for a vaccine against genital herpes** S. Delagrave*, C. Zhou, H. Hernandez, S. Mundle, J. Hamberger, S. Baloglu, J. Catalan, S. Pougatcheva, S. Anderson, P. Londoño-Hayes, H. Kleanthous, *Sanofi Pasteur, USA*
[P1.2.2]	**Pneumococcal Surface Protein A as an active carrier protein in conjugates using polysaccharide serotype 6B of *Streptococcus pneumoniae*** C.T. Perciani*, C. Goulart, E. Carvalho, G.C. Barazzone, V.M. Gonçalves, M.M. Tanizaki, *Instituto Butantan, Brazil*
[P1.2.3]	**A new conjugation strategy: TEMPO-mediated synthesis of Campylobacter jejuni and Clostridium difficile glycoconjugate vaccines and immunodetection thereof** M.A. Monteiro*[1], Y.H. Chen[1], Z. Ma[1], P. Guerry[2], *[1]University of Guelph, Canada, [2]US Naval Medical Center, USA*
[P1.2.4]	**Estimated coverage of Canadian Meningococcal B isolates by a meningococcal serogroup B vaccine** J.A. Bettinger*[1], D.W. Scheifele[1], S.A. Halperin[2], N. Le Saux[3], W. Vaudry[4], J. Findlow[5], D. Medini[6], R. Tsang[7], *[1]University of British Columbia, Canada, [2]Dalhousie University, Canada, [3]Children's Hospital of Eastern Ontario, Canada, [4]University of Alberta, Canada, [5]Health Protection Agency, UK, [6]Novartis Vaccines, Italy, [7]Public Health Agency of Canada, Canada*
[P1.2.5]	**Protective linear epitopes in *Ehrlichia chaffeensis* tandem repeat proteins** J. Kuriakose, X. Zhang, L. Tian, J. McBride*, *University of Texas Medical Branch, USA*
[P1.2.6]	**A new fully synthetic analog of type A Neisseria meningitidis capsular polysaccharide antigen is immunoactive** S. Fallarini[1], T. Paoletti[1], L. Lay[2], G. Lombardi*[1], *[1]University of Piemonte Orientale, Italy, [2]University of Milano, Italy*
[P1.2.7]	**Evaluation of meningococcal C conjugate vaccine programs in Canadian children: Interim analysis** J.A. Bettinger*[1], D.W. Scheifele[1], S.A. Halperin[2], J.D. Kellner[3], A. Schryvers[4], G. De Serres[5], *[1]University of British Columbia, Canada, [2]Dalhousie University, Canada, [3]University of Calgary, Canada, [4]University of Calgary, Canada, [5]Institut National de Sante Publique, Canada*
[P1.2.8]	**A modular approach for assembly of lipopeptide-based vaccines allows conformational epitope building** K.J. Horrocks*, W. Zeng, G. Robevska, C.Y. Wong, K. Azzopardi, M. Tauschek, *The University of Melbourne, Australia*
[P1.2.9]	**Serologic markers for long-term immunity in humans vaccinated with live *Yersinia pestis* EV NIIEG** V. Feodorova[1], A. Lyapina[1,2], O. Ulianova[1,3], E. Lyapina[2], L. Sayapina[4], V. Motin*[5], *[1]Saratov State Veterinary Institute, Russia, [2]Saratov State Medical University, Russia, [3]Saratov State University, Russia, [4]Tarasevich Institute, Russia, [5]University of Texas Medical Branch, USA*
[P1.2.10]	**Identifying protective antigens of *Staphylococcus aureus,* a pathogen that suppresses host immune responses** H.K. Kim, O. Schneewind, D. Missiakas*, *The University of Chicago, USA*
[P1.2.11]	**Bioinformatic-driven H. pylori vaccine design** S.F. Moss[1], A.S. De Groot*[2,5], L. Moise[2,4], J. Fueyo[3], *[1]Rhode Island Hospital & Warren Alpert Medical School of Brown University, USA, [2]EpiVax, Inc., USA, [3]College of Pharmacy, University of Rhode Island, USA, [4]Institute for Immunology and Informatics, University of Rhode Island, USA, [5]Warren Alpert Medical School of Brown University, USA*
[P1.2.12]	**Pan-burkholderia vaccine development integrating genomics and immunoinformatics** J. Desrosiers[1], L. Moise*[1,2], E. Gustafson[1], M. Ardito[2], G. Tejada[1], B. Martin[2], A.S. De Groot[1,3], *[1]University of Rhode Island, USA, [2]EpiVax, Inc, USA, [3]Brown University Warren Alpert Medical School, USA*

[P1.2.13]	**Antibody against *Haemophilus influenzae* protein D in adults with chronic conditions causing secondary immunodeficiency** M. Ulanova*, N. Hawdon, B. Biman, W. McCready, M. Brigden, S. Malik, *Northern Ontario School of Medicine, Canada*
[P1.2.14]	**Intranasal immunization with PcsB of *Streptococcus pneumoniae* reduces nasopharyngeal colonization of mice with the pneumococcus** L.S. McDaniel*, M.F. Mills, *University of Mississippi Medical Center, USA*
[P1.2.15]	**Durable immunity following tetanus/diphtheria vaccination suggests reevaluation of the current adult vaccine schedule** B.A. Poore*[1], E. Hammarlund[2], A. Rynko[2], A. Thomas[2], M.K. Slifka[1,2], *[1]Najit Technologies Inc., USA, [2]Oregon Health Sciences University, USA*
[P1.2.16]	**Have changing pneumococcal vaccination programs impacted disease in Ontario: The past, present and future?** G.H. Lim[1], A. McGeer[2,3], D. Pillai[1,4], W. Rudnick[5], B. Sander[1], A. Wormsbecker[2,6], D. Low[1], N.S. Crowcroft[1], S.L. Deeks*[1,2], *[1]Public Health Ontario, Canada, [2]University of Toronto, Canada, [3]TIBDN Influenza Study Group, Canada, [4]University Health Network, Canada, [5]Mount Sinai Hospital, Canada, [6]Hospital for Sick Children, Canada*
[P1.2.17]	**Bioinformatic-driven *H. pylori* vaccine design** S.F. Moss[1], S. Zhang[1], M. Ardito[2], F. Terry[2], J. Fueyo[3], K. DaSilva[4], W. Martin[2], A.S. De Groot[2,5], L. Moise*[2,4], *[1]DRhode Island Hospital and Warren Alpert Medical School of Brown University, USA, [2]EpiVax, Inc., USA, [3]Boston University, USA, [4]University of Rhode Island, USA, [5]Brown University Warren Alpert School of Medicine, USA*
[P1.2.18]	**Evaluating the effectiveness of conjugated pneumococcal vaccines in Colombia** N.I. Manjarres-Posada, L.A. Choconta-Piraquive*, F. De la Hoz-Restrepo, *Universidad Nacional de Colombia, Colombia*
[P1.2.19]	**A whole cell pertussis vaccine with reduced content of LPS protects mice against infection with Bordetella parapertussis** W.O. Dias*, L.F.R. Cruz, C.L. Pinto, M.E.S. Almeida, E.P. Silva, I. Raw, *Instituto Butantan, Brazil*
[P1.2.20]	**Distribution of *Streptococcus pneumoniae* serotypes among global populations** M. Hackel*[1], C. Lascols[1], S. Bouchillon[1], B. Hilton[2], D. Morgenstern[2], J. Purdy[2], *[1]International Health Management Associates, USA, [2]Pfizer Inc, USA*
[P1.2.21]	**Development of a vaccine against *Clostridium difficile* infection: Design, purification and biological activities of recombinant toxin antigen fragments** J. Karczewski*, S. Secore, J. Zorman, S. Wang, *Merck & Co., Inc., USA*
[P1.2.22]	**Therapeutic efficacy of a *Helicobacter pylori* vaccine dependent on antibodies and T-cells** F. Anderl*, K. Goller, C. Bolz, B. Kalali, D.H. Busch, M. Gerhard, *Technische Universität München, Germany*
Human vaccines, infectious diseases (other)	
[P1.3.1]	**Engineering transgenic carrots to aid in the fight against malaria** J.L. Johnson*, M.H. Eulenstein, L.E. Nieman, S.M. Keenan, *University of Northern Colorado, USA*
[P1.3.2]	**Antibodies to plant-produced *Plasmodium falciparum* sexual stage proteins Pfs25 and Pfs230 exhibit transmission blocking activity** J.A. Chichester[1], R.W. Sauerwein[2], T. Tsuboi[3], Y. Wu[4], V. Yusibov*[1], *[1]Fraunhofer USA Center for Molecular Biotechnology, USA, [2]Radboud University Nijmegen Medical Center, The Netherlands, [3]Ehime University, Japan, [4]National Institutes of Health, USA*
[P1.3.3]	**Chemical and immunological aspects of polysaccharide-protein conjugate activated by DMT-MM** G.C. Barazzone*, C.T. Perciani, M.A. Silva, M.M. Tanizaki, *Instituto Butantan, Brazil*
[P1.3.4]	**DNA vaccination against cutaneous leishmaniasis By pCMV-LACK construct in BALB/c mice** S. Khanjani Jafroodi*, M.R. Razavi, M. Assmar, *Pasteur Institute of Iran, Iran*
[P1.3.5]	**Antigen-specific enhancement of natural human IgG antibodies to lipids induced by a liposomal vaccine containing lipid A and a protein antigen** G.R. Matyas*, C.R. Alving, *Walter Reed Army Institute of Research, USA*
[P1.3.6]	**A PP7 bacteriophage virus-like particle display platform for peptide epitope identification using affinity-selection** E. Crossey*, J. O'Rourke, D. Peabody, B. Chackerian, *University of New Mexico, USA*
[P1.3.7]	**A multi-component heterologous DNA/protein vaccine is protective against *Trypanosoma cruzi* infection in mice** S. Gupta*, N.J. Garg, *University of Texas Medical Branch, USA*
[P1.3.8]	**Epitope selection for a transmission-blocking vaccine against tick-borne diseases** F. Terry[1], T.N. Mather[2], J.M. Ribeiro[1], A.S. De Groot[1,4], J.M.C. Ribeiro[3], C. Boyle*[1], *[1]EpiVax, Inc., USA, [2]Center for Vector-Borne Disease, University of Rhode Island, USA, [3]National Institutes of Health, USA, [4]Institute for Immunology and Informatics, University of Rhode Island, USA*

[P1.3.9]	**Comparative assessment of transmission blocking malaria vaccine candidate antigens using an adenovirus-MVA prime-boost regime** M.C. Kapulu*[1], S. Biswas[1], K. Miura[2], A.M. Blagborough[3], A.R. Williams[1], A.L. Goodman[1], A. Nicosia[4], T. Tsuboi[5], *[1]University of Oxford, UK,[2]NIH, USA,[3]Imperial College London, UK,[4]Okairois AG, Italy,[5]Ehime University, Japan*
[P1.3.10]	**Development of a malaria vaccine based on full-length Merozoite Surface Protein (MSP)-1 from *P. falciparum*** H. Bujard*, C. Epp, *University of Heidelberg, Germany*
[P1.3.11]	**Comparative immunogenicity of Na-GST-1 human hookworm vaccine with synthetic glucopyranosyl lipid adjuvant (GLA) in BALB/c mice** A.R. Jariwala*[1], B. Keegan[2], J.L. Plieskat[2], M.E. Bottazzi[2], P.J. Hotez[1,4], J.M. Bethony[2,3], *[1]Albert B. Sabin Vaccine Institute, USA,[2]George Washington University, USA,[3]Fundação Oswaldo Cruz, Brazil,[4]Baylor College of Medicine, USA*
Human vaccines, non-infectious diseases	
[P1.4.1]	**Evaluation of an immunoprophylactic strategy against low molecular weight carcinogens based on benzo[a]pyrene** M.T. Schellenberger*, S. Farinelle, S. Willième, C.P. Muller, *Institute of Immunology, Luxembourg*
[P1.4.2]	**Identification and characterization of a novel antigen MMSA-1 in multiple myeloma** F.L. Zhou*, S. Meng, W.G. Zhang, *Xi'an JiaoTong University, China*
Immunology / Animal models	
[P1.5.1]	**Sequential H1N1 infections elicit cross-reactive antibodies against emerging pandemic H1N1 influenza viruses** D.M. Carter*[1], C.J. Crevar[1], B.M. Giles[1], H.R. Lu[1], C.E. Bloom[1], J.L. Cherry[2], D.J. Lipman[2], T.M. Ross[1], *[1]University of Pittsburgh, USA,[2]National Institutes of Health, USA*
[P1.5.2]	**Partial contribution of the B2 receptor of the kinin inflammation pathway in protection against murine visceral leishmaniasis by the C-terminal domain of nucleoside hydrolase vaccine** D. Nico, D.F. Feijó, J. Scharfstein, A. Morrot, C.B. Palatnik de Sousa*, *Universidade Federal do Rio de Janeiro, Brazil*
[P1.5.3]	**Cloning of the C-terminal domain peptides of *Leishmania donovani* nucleoside hydrolase (NH36) aiming the identification of antibody epitopes** D. Nico[1], I.S. Soares[2], M.M. Rodrigues[3], M. Palatnik[1], C.B. Palatnik de Sousa*[1], *[1]Universidade Federal do Rio de Janeiro, Brazil,[2]Universidade de São Paulo, Brazil,[3]Universidade Federal de São Paulo, Brazil*
[P1.5.4]	**The C-terminal and N-terminal domain peptides of *Leishmania donovani* nucleoside hydrolase (NH36) in mice cross-protection against Leishmania amazonensis infection** B.S. Lima[1], D. Nico[1], I.S. Soares[2], M.M. Rodrigues[3], C.B. Palatnik de Sousa*[1], *[1]Universidade Federal do Rio de Janeiro, Brazil,[2]Universidade de São Paulo, Brazil,[3]Universidade Federal de São Paulo, Brazil*
[P1.5.5]	**Immunotherapy with the Leishmune®'s Nucleoside hydrolase DNA vaccine reduces infection and increases survival in a canine experimental model of visceral leishmaniasis** F.B. Santos[1], G.P. Borja-Cabrera[1,3], D. Nico[1], L. Mana[2], M. Palatnik[1], C.B. Palatnik de Sousa*[1], *[1]Universidade Federal do Rio de Janeiro, Brazil,[2]Università di Napoli Federico II, Italy,[3]Universidade Vale do Rio Doce, Brazil*
[P1.5.6]	**Strong innate immunity to M13 bacteriophage: Implication for vaccine development** S. Hashiguchi*, T. Gotanda, Y. Hamazoe, T. Tsurumaru, K. Sugimura, *Kagoshima University, Japan*
[P1.5.7]	**Global transcriptional response to ISCOM matrix at the site of administration and in draining lymph nodes after intramuscular injection in pigs** V. Ahlberg*[1], K. Lövgren Bengtsson[2], P. Wallgren[3], C. Fossum[1], *[1]Swedish University of Agricultural Sciences, Sweden,[2]Isconova AB, Sweden,[3]National Veterinary Institute, Sweden*
[P1.5.8]	**Virus-like particle vaccines with HIV and RSV antigens produce immune responses in human PBL engrafted NOD scid IL-2Rgc$^{-/-}$ mice** M.R. Schmidt[1], T.G. Morrison*[1], K.N. Willems[1], L.W. McGinnes[1], G.K. Lewis[2], R.T. Woodland[1], *[1]University of Massachusetts Medical School, USA,[2]University of Maryland, USA*
[P1.5.9]	**Mouse immunization with fusion proteins including fragments of pneumococcal surface protein A (PspA) and detoxified mutants of Pneumolysin (Pds) induces antibodies capable of mediating complement deposition on the Streptococcus pneumoniae surface** C. Goulart[1], T.R. Silva[2], L.C.C. Leite[1], M. Darrieux*[2], *[1]Instituto Butantan, Brazil,[2]Universidade São Francisco, Brazil*
[P1.5.10]	**Mice vaccination with high hydrostatic pressure-inactivated H3N8 protects against experimental avian flu** S.P.C. Barroso*, D. Nico, A.C.S. Vicente, *Universidade Fedeal do Rio de Janeiro, Brazil*
[P1.5.11]	**Immunotherapy of pythiosis: Effect on adenosine deaminase activity in lymphocytes of an experimental model** B.C. Bach, J.A.S. Jaques, V.C.G. Souza, J.B. Ruchel, K.B. Schlemmer, R.A. Zanette*, *Universidade Federal de Santa Maria, Brazil*
[P1.5.12]	**Characterization of immune system response across microarray data from gene expression omnibus** S. Raghunath*, L.J. Frey, *University of Utah, USA*
[P1.5.13]	**Bioinformatics analysis of protective antigens in manually curated Protegen database** Z. Xiang*, Y. He, *University of Michigan Medical School, USA*

[P1.5.14]	**VIOLIN: An integrative vaccine research database and analysis system** Y. He*, Z. Xiang, *University of Michigan, USA*
[P1.5.15]	**Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines** B. Chua*[1], M. Kobiasi[2], W. Zeng[1], D. Mainwaring[2], D. Jackson[1], *[1]The University of Melbourne, Australia, [2]Royal Melbourne Institute of Technology, Australia*
[P1.5.16]	**Filamentous phage as a model for tracking B-cell responses during early and chronic infection** A. Murira[1], K.A. Henry[1], J. Holland[1], J.K. Scott*[1,2], *[1]Dept. Molecular Biology and Biochemistry, Simon Fraser University, Canada, [2]Faculty of Health Sciences, Simon Fraser University, Canada*
[P1.5.17]	***Neisseria lactamica* antigens complexed with a novel cationic adjuvant** E.B. Gaspar[1], A.S. Rosetti[1], N. Lincopan[1], E. De Gaspari*[1,2], *[1]São Paulo University, Brazil, [2]Adolfo Lutz Institute, Brazil*
[P1.5.18]	**The infection site of Leishmania major parasites influences the performance of Leish-111f intranasal immunization** Y. Matsumoto*, F. Gen, Y. Iwasaki, Y. Ojima, Y. Takada, Y. Matsumoto, S.G. Reed, *University of Tokyo, Japan*
[P1.5.19]	**Development and evaluation a new dendrimer based nano formulated DNA vaccine for rabies** P.T. Ullas[1], S.N. Madhusudana[1], D. Anita[1], N. Jayaraman[2], *[1]National Institute of Mental health & Neurosciences, India, [2]Indian Institute of Science, India*
[P1.5.20]	**Novel T cell driven approach leads to the identification of immunoprevalent antigens** V. Judkowski[1], R. G. Santos[2], , M. K. Slifka[3], D. C. Douek4, B. S. Graham[4], C. Pinilla[1]*, *[1]Torrey Pines Institute for Molecular Studies, USA, [2]Torrey Pines Institute for Molecular Studies, USA, [3] Vaccine and Gene Therapy Institute, Oregon Health & Science University, USA, [4] Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA*
[P1.5.21]	**GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination** V. Judkowski[1], A. Bunying[1], F. Ge[1], J. R. Appel[1], K. Law[1], A. Sharma[1], C. Raja-Gabaglia[1], P. Norori[1], R. G. Santos[2], M. A. Giulianotti[2], M. K. Slifka[3], D. C. Douek[4], B. S. Graham[4], C. Pinilla[1]*, *[1]Torrey Pines Institute for Molecular Studies, USA, [2]Torrey Pines Institute for Molecular Studies, USA, [3] Oregon Health & Science University, USA, [4] Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA*

Poster Session 2
Monday 3 October, 13:30 – 15:30

Human vaccines, infectious diseases (viruses)	
[P2.1]	**Compliance of General hospitals' staff regarding Influenza Immunization, Shiraz South-Iran** B. Honarvar*[1,2], S. Alighanbari[1], K. Baliani[1], *[1]SHIRAZ UNIVERSITY OF MEDICAL SCIENCES, Iran, [2]Health Policy Research Center, Iran*
[P2.2]	**Immunogenicity and efficacy of dengue virus serotype 2 vaccine candidates in African green monkey** K. Nanda[1], K.M. Smith[1], C.J. Spears[1], A. Piper[2], M. Ribeirio[2], R. Hernandez[2], M. Thomas*[1], *[1]Arbovax Inc., USA, [2]North Carolina State University, USA*
[P2.3]	**The live attenuated Japanese Encephalitis Vaccine SA 14-14-2 in children: A review of safety and tolerability** A.S. Ginsburg*[1,2], M. Yaich[1,2], *[1]PATH, USA, [2]PATH, France*
[P2.4]	**the Elimination plan of measles in Canary Islands 2001-2010** A.J. García Rojas*[1], P. Matute Cruz[1], P. García Castellano[1], N. Abadía Benítez[1], J. Solís Romero[1], D. Trujillo Herrera[1], M.C. Pérez González[2], F. Artiles Campelo[2], *[1]Public Health Service, Spain, [2]Microbiology Service. Gran Canaria Hospital, Spain*
[P2.5]	**Effectiveness of the seasonal 2010-2011 influenza vaccine to prevent laboratory confirmed influenza related hospitalizations. Hospital based, case-case comparison, case-control study, Valencia, Spain** J. Puig-Barbera*[1,7], S. Perez-Vilar[1], J.L. Micó-Esparza[2], A. Beleguer-Varea[3], C. Carratala-Munuera[4], G. Schwarz-Chavarri[5], J. García-Lomas[6], A. Arnedo-Pena[7], B. Escribano-López[1], V. Alcarria-García[1], E. Huet-Trujillo[1], A. López - Doménech[1], M. Cano-Armenteros[1], M. Ruiz-García[7], C. Calvo-Mas[7], J. Díez-Domingo[1], *[1]Centro Superior de Investigación en Salud Pública (SISP), Spain, [2]Hospital Arnau de Vilanova (Valencia), Spain, [3]Hospital de la Ribera (Alzira), Spain, [4]Universidad Miguel Hernández, Spain, [5]Centro de Salud San Blas (Alicante), Spain, [6]Instituto Valenciano de Micobiología (IVAMI), Spain, [7]Centro de Salud Pública de Castellón, Spain*
[P2.6]	**Iranian nurses knowledge, attitude and behavioral changes towards influenza and its vaccination during 2009 H1N1 pandemic** B. Honarvar[1], F. Ghaffarpasand[2], S. Alighanbari[3], M. Sayadi[3], E. Minsef*[1], *[1]Shiraz University Of Medical Sciences, Iran, [2]Fasa Medical University, Iran, [3]Shiraz University Of Medical Sciences, Iran*
[P2.7]	**Immunogenicity of 17DD Yellow Fever Vaccine in dose-response study** R. Martins*[1], M.L. Maia[1], R.H. Farias[1], L.A. Camacho[2], M. Freire[1], A. Homma[1], *[1]Bio-Manguinhos, Brazil, [2]Fiocruz, Brazil*
[P2.8]	**Infuenzae Vaccine coverage in older people than 65 years. Canary Islands 2001-2010** A.J. García Rojas*, D. Nuñez Gallo, D. Trujillo Herrera, J. Solís Romero, P. García Castellano, P. Matute Cruz, *Public Health Service, Spain*
[P2.9]	**Examining HIV-1 clade C recombinant envelope glycoproteins in vaccines: Gp140 vs gp120** A. Nandi*[1], C. Zambonelli[1], Y. Sun[1], M. Montefiori[2], A. Dey[1], S. Barnett[1], *[1]Novartis Vaccines, USA, [2]Duke University Medical Center, USA*
[P2.10]	**Modified Glycoprotein D DNA vaccines protect against challenge in an HSV-2 infection model** J. Dutton[3], B. Li[3], W.P. Woo[3], J.O. Marshak[1], I. Frazer[2,3], D. Koelle*[1], *[1]University of Washington, USA, [2]University of Queensland Diamantina Institute, Australia, [3]Coridon Pty. Ltd., Australia*
[P2.11]	**Dynamics of the bacterially expressed conserved immunogenic region of the human respiratory syncytial virus G protein** F. Azizi Jalilian*[1,2], F. Jahanshiri[2], R. Amini[3,2], Z. Sekawi[2], S.S. Suhaimi[2], K. Yusoff[2], *[1]Ilam University of Medical Sciences, Iran, [2]University Putra, Malaysia, [3]Hamadan University of Medical Sciences, Iran*
[P2.12]	**Development of a novel oral DNA vaccine delivered by *Salmonella typhi Ty21a* against respiratory syncytial virus** R. Amini*[1,2], F. Azizi Jalilian[2,3], F. Jahanshiri[2], S.S. Suhaimi[2], Z. Sekawi[2], K. Yussof[2], *[1]Hamadan University of Medical Sciences, Iran, [2]University of Putra Malaysia, Malaysia, [3]Ilam University of Medical Sciences, Iran*
[P2.13]	**Factors associated with high levels of measles, rubella, mumps and varicella antibodies among Japanese university students** J. Takeuchi*[1], M. Goto[1], T. Kawamura[1], A. Hiraide[2], *[1]Kyoto University Health Service, Japan, [2]Kinki University Faculty of Medicine, Japan*
[P2.14]	**The highly conserved HA2 glycopeptide of Influenza A Virus induces cross protective immune response** M. Chowdhury*[1], Y.K. Choi[2], H.J. Moon[1], J.S. Lee[1], C.J. Kim[1], *[1]Chungnam National University, Republic of Korea, [2]Chungbuk National University, Republic of Korea*
[P2.15]	**Mucosal immunization of recombinant HA protein with chitosan/poly gamma-glutamate nanoparticles protects mice against highly pathogenic Influenza A virus by induced neutralizing antibodies and cytotoxic T lymphocyte response** H.J. Moon[1], Y.K. Choi[1], J.H. Kim[1], M.E. Park[1], M.H. Sung*[2,3], J.S. Lee[1], C.J. Kim[1], *[1]Chungnam National University, Republic of Korea, [2]Kookmin University, Republic of Korea, [3]BioLeaders Corporation, Republic of Korea*

[P2.16]	**Cross protective immunity of Influenza A Virus consensus 1XM2e and four linking of M2e extracellular domain (4XM2e)** M. Chowdhury*[1], Y.K. Choi[2], H.J. Moon[1], J.S. lee[1], C.J. Kim[1], *[1]Chungnam National University, Republic of Korea, [2]Chungbuk National University, Republic of Korea*
[P2.17]	**Evaluation of Hepatitis B Vaccine immunogenicity among older adults during an outbreak response in assisted living facilities** R. Tohme*[1], D. Awosika-Olumo[2], C. Nielsen[1], J. Drobeniuc[1], S. Khuwaja[2], P. Spradling[1], *[1]Centers for Disease Control and Prevention, USA, [2]Houston Department of Health and Human Services, USA*
[P2.18]	**The immunobiology of oil-in-water adjuvants for influenza vaccines** K.K. Yam*[1], D.W. Scheifele[2], B.J. Ward[3], *[1]McGill University, Canada, [2]University of British Columbia, Canada, [3]Research Institute of the McGill University Health Centre, Canada*
[P2.19]	**Pregnant women's knowledge, attitudes, and beliefs about influenza vaccination** M. Henninger[1], A. Naleway*[1], B. Crane[1], J. Donahue[2], S. Irving[2], B. Kieke[2], *[1]Kaiser Permanente Center for Health Research, USA, [2]Marshfield Clinic Research Foundation, USA*
[P2.20]	**Trends in influenza vaccine coverage in pregnant women, 2008-2011** A. Naleway*, M. Henninger, B. Crane, *Kaiser Permanente Center for Health Research, USA*
[P2.21]	**Influenza A (H1N1) MF59-adjuvanted vaccine and adverse perinatal outcomes (preliminary analysis)** F. Rubinstein*[1,2], P. Micone[4], A. Bonotti[1], V. Weiner[4], F. Augustovski[1,3], *[1]Institute of Clinical Effectiveness and Health Policy, Argentina, [2]University of Buenos Aires, Argentina, [3]Hospital Italiano de Buenos Aires, Argentina, [4]Centro de Investigación en Salud Poblacional (CISAP), Argentina*
[P2.22]	**Study on the standardization of *in vitro* potency test for Hepatitis B vaccine** S.H. Kim*, D.K. Kim, S.H. Hong, H.S. Yoon, J.O. Kim, *Korea Food and Drug Administration, Republic of Korea*
[P2.23]	**Single nucleotide polymorphism among vaccine and clinical strains of Varicella-zoster virus** C.H. Lee*[1], G.Y. Ji[1], J.I. Kim[1], G.S. Jung[1], Y.Y. Kim[1], H.S. Kim[1], S.Y. Park[2], K.M. Lee[3], *[1]Department of Microbiology, CBITRC, Chungbuk National University, Republic of Korea, [2]Mogam Biotechnology Research Institute, Republic of Korea, [3]Department of Computer Science, CBITRC, Chungbuk National University, Republic of Korea*
[P2.24]	**GLA-SE, a synthetic TLR4 agonist, enhances T cell responses to influenza vaccine in older adults** H. Behzad*[1], A. Huckreide[2], L. Haynes[3], T.R. Kollmann[4], S. Reed[5], J.E. McElhaney[1], *[1]Vancouver Coastal Health Research Institute, University of British Columbia, Canada, [2]University Medical Center, The Netherlands, [3]Trudeau Institute, USA, [4]Children and Families Research Institute, University of British Columbia, Canada, [5]Immune Design Corporation, USA*
[P2.25]	**Elucidation and mapping of neutralizing epitope of 5S, a high affinity antibody against Hepatitis B surface antigen by phage display library** A. Tiwari*[1], A. Sankhyan[1], N. Khanna[2], S. Sinha[1], *[1]All India Institute of Medical Sciences, India, [2]International Center for Genetic Engineering and Biotechnology, India*
[P2.26]	**Efficacy of a vesicular stomatitis virus vector capable of simultaneously expressing the H5N1 influenza HA and Ebolavirus glycoprotein antigens** S. Schindle*[1], G. Wong[1,2], H. Ebihara[3], H. Feldmann[3], G.P. Kobinger[1,4], *[1]Public Health Agency of Canada, Canada, [2]Department of Medical Microbiology, University of Manitoba, Canada, [3]National Institute of Allergy and Infectious Disease, USA, [4]Department of Immunology, University of Manitoba, Canada*
[P2.27]	**Short-term safety of the 2010-11 seasonal influenza vaccine in pregnancy and a comparison with the 2009-10 pH1N1 and seasonal influenza vaccines** J. Donahue[1], M. Henninger[2], S. Irving*[1], B. Kieke[1], B. Crane[2], D. Cole[1], *[1]Marshfield Clinic Research Foundation, USA, [2]Kaiser Permanente Northwest, USA*
[P2.28]	**Clinical development of a plant-derived H1N1 recombinant hemagglutinin influenza vaccine** V. Yusibov*[1], J. Chichester[1], Y. Shoji[1], J.M. Katz[2], J.F. Cummings[3], *[1]Fraunhofer USA Center for Molecular Biotechnology, USA, [2]Centers for Disease Control and Prevention, USA, [3]Walter Reed Army Institute of Research, USA*
[P2.29]	**Heterologous neutralizing activity of Japanese encephalitis virus genotype III formalin-inactivated Nakayama vaccine against emerging genotype I virus** Y.C. Fan[1], J.M. Chen[1], Y.Y. Chen[1], C.C. Shih[2], G.J. Chang[3], S.S. Chiou*[1], *[1]National Chung Hsing University, Taiwan, [2]Mennonite Christian Hospital, Taiwan, [3]Center for Disease Control and Prevention, USA*
[P2.30]	**An investigation of inflammatory mediators in selected adverse events following influenza immunization in adults** M.A. Al-Dabbagh[1], K. Lapphra[1], D.W. Scheifele[1], S. Dobson[1], S.A. Halperin[2], J.A. Bettinger*[1], D. Skowronski[3], G. De Serres[4], *[1]Vaccine Evaluation Center, University of British Columbia, Canada, [2]Dalhousie University, Canada, [3]British Columbia Centre for Disease Control, University of British Columbia, Canada, [4]Unité de Recherche en Santé Publique (CHUQ), Canada*
[P2.31]	**Epidermal vaccination of hepatitis A using a dissolving microneedle array** S. Naito*[1], Y. Ito[2], T. Kiyohara[1], M. Kataoka[1], M. Ochiai[1], K. Takada[2], *[1]National Institute of Infectious Diseases, Japan, [2]Kyoto Pharmaceutical University, Japan*

[P2.32]	**Development of haemagglutinin gene/protein based vaccine for 2009 pandemic H1N1 (pH1N1-09) influenza** V.A. Arankalle, *National Institute of Virology, India*
[P2.33]	**Humanized monoclonal antibody for overcoming of drug resistant herpes simplex virus infections** A. Krawczyk*[1], J. Krauss[2], M. Arndt[2], A. Eis-Huebinger[3], K. Schneweis[3], M. Roggendorf[1], C.R. Martin[4], L. Grosse-Hovest[5], *[1]University Hospital of Essen, Germany, [2]National Center for Tumor Diseases (NCT) Heidelberg, Germany, [3]University Hospital of Bonn, Germany, [4]University College London, UK, [5]University of Tuebingen, Germany*
[P2.34]	**Targeting the "Achilles' Heel" of HIV: Validation of immunogenic HLA-A2 epitopes conserved across time and sequence for the GAIA HIV vaccine** O.A. Koita[1], K. Sangare[1], A.S. De Groot*[4,5], J. Rozehnal[3], M.A. Ardito[2], *[1]University of Bamako, Mali, [2]EpiVax, Inc., USA, [3]University of Rhode Island, USA, [4]GAIA Vaccine Foundation, Mali, [5]Warren Alpert Medical School of Brown University, USA*
[P2.35]	**Flavivirus-specific CD4+ T cell responses in health and disease** E.A. James*[1], R.E. LaFond[1], T.J. Gates[1], D. Mai[1], U. Malhotra[2], W.W. Kwok[1,3], *[1]Benaroya Research Institute, USA, [2]Virginia Mason Medical Center, USA, [3]University of Washington, USA*
[P2.36]	**iVAX web-based vaccine design: Application to a hepatitis C virus vaccine** M. Ardito*[1], S.H. Gregory[2], A.S. De Groot[1,3], *[1]EpiVax, Inc., USA, [2]Rhode Island Hospital and the Warren Alpert Medical School of Brown University, USA, [3]University of Rhode Island, USA*
[P2.37]	**Immunogenicity and efficacy of Flagellin-HA Vaccines against Highly Pathogenic Avian Influenza Viruses (HPAIV) H5N1 in mice and ferrets** G. Liu*[1], L. Song[1], L. Reiserova[1], U. Trivedi[1], D. Noah[2], H. Li[1], *[1]VaxInnate Corporation, USA, [2]Southern Research Institute, USA*
[P2.38]	**An adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes** R. Veselenak*[1], S. Sullivan[2], M. Shlapobersky[2], Q. Wei[2], R. Pyles[1], N. Bourne[1], *[1]University of Texas Medical Branch, USA, [2]Vical, USA*
[P2.39]	**Demographics of acute care health care workers who seroconverted after receipt of the Influenza A (H1N1) 2009 monovalent vaccine** K. Alagappan*[1], M. Ward[1], S. DeCicco[1], J. Katz[2], F. Dawood[2], R. Silverman[1], *[1]North Shore -Long Island Jewish Health System, USA, [2]Centers for Disease Control and Prevention, USA*
[P2.40]	**Seropositivity to the 2009 pandemic H1N1 influenza virus among emergency department health care workers** K. Alagappan*[1], R. Silverman[1], M. Ward[1], F. Dawood[2], S. DeCicco[1], J. Katz[2], *[1]North Shore-Long Island Jewish Health System, USA, [2]Centers for Disease Control and Prevention, USA*
[P2.42]	**Development of a novel H_2O_2-based vaccine platform** I.J. Amanna*[1], H.P. Raué[2], M.K. Slifka[1,2], *[1]Najít Technologies, Inc., USA, [2]Oregon Health & Sciencies University, USA*
[P2.43]	**Recombinant micellar RSV F vaccine for respiratory disease: Antigen characterization, preclinical efficacy and clinical evaluation** G. Glenn*, R. Raghunandan, G. Smith, B. Zhou, *Novavax, USA*
[P2.44]	**Computational design of conformationally intact immunogen for the elicitation of protective antibody immune response** M. Manish*[1,2], R. Samudrala[1], J. Mullins[1], A. Centurion[1], M. Mendoza[3], M. Zimic[3], R. Bhatnagar[2], *[1]University Of Washington, USA, [2]Jawaharlal Nehru University, India, [3]Universidad Peruana Cayetano Heredia, Peru*
[P2.45]	**Immunoinformatic discovery of potential cross-reactive T cell epitopes in the measles genome** L. Moise*[1,2], M. Ardito[2], W. Martin[2], A.S. DeGroot[2,3], *[1]University of Rhode Island, USA, [2]EpiVax, Inc., USA, [3]Brown University Warren Alpert Medical School, USA*
[P2.46]	**Persistence of influenza vaccine-induced antibodies in healthy individuals and lung transplant patients** M. Hayney*, J. Severson, J. Moran, *University of Wisconsin School of Pharmacy, USA*
[P2.47]	**Viral infections: Occupational risk for pregnant healthcare workers?** S. Wicker, *University Hospital Frankfurt, Germany*
[P2.48]	**Preclinical development of a live-attenuated Chikungunya vaccine** J.A. Livengood[1], *[1]Inviragen, Inc., USA, [2]University of Texas Medical Branch, USA, [3]University of Wisconsin, USA*
[P2.49]	**Small molecule agonists of the RIG-I pathway and their potent immune pathway stimulation and broad antiviral actions** K.M. Bedard*[1], M.L. Wang[1], Y.M. Loo[2], M.G. Katze[2], M. Gale Jr.[2], S.P. Iadonato[1], *[1]Kineta, Inc., USA, [2]University of Washington, USA*
[P2.50]	**Rotavirus vaccine effectiveness against diarrhea hospitalizations in Colombia** F. De la Hoz-Restrepo*[1], N. Alvis-Guzman[2], A. Porras[1], N. Cediel[1], A. Rico[1], *[1]Universidad Nacional de Colombia, Colombia, [2]Universidad de Cartagena, Colombia*
[P2.51]	**Dissecting influenza vaccine induced CD4+ T cell responses** J. Yang*, N. Torres-Chinn, D. Mai, G. Doronio, W.W. Kwok, *Benaroya Research Institute, USA*
[P2.52]	**Influenza vaccination among adults aged 65 or older in the United States** M. Takayama*[1,2], C.M. Wetmore[1], A.H. Mokdad[1], *[1]University of Washington, USA, [2]University of Tokyo, Japan*

[P2.53]	**Influenza vaccination in medical students and intention to get the shot: Online versus offline strategies** G. Mena*, A. Llupià, M. Aldea, G. Sequera, J.M. Bayas, A. Trilla, *Hospital Clínic of Barcelona, Spain*
[P2.54]	**MPER peptides with anionic modifications retain monoclonal antibody binding and generate high titer antisera in rabbit immunizations** V.J. Venditto*[1], D.S. Watson[2], F.C. Szoka, Jr.[1], *[1]University of California, USA, [2]SRI International, USA*
[P2.55]	**Assessment of the feasibility of a different HIV vaccine approach** M. Luo*[1,2], R. Capina[1], C. Daniuk[1], T. Ball[3], J. Kimani[3,4], F. Plummer[1,2], *[1]National Microbiology Laboratory, Canada, [2]University of Manitoba, Canada, [3]Public Health Agency of Canada, Canada, [4]University of Nairobi, Kenya*
[P2.56]	**A Respiratory Syncytial Virus (RSV) nanocapsule vaccine containing a G protein peptide payload induces robust B and T cell immunity and protects from infection and disease** P.A. Jorquera*[1], Y. Choi[1], J. Powell[2], L.M. Haynes[3], L.J. Anderson[4], R.A. Tripp[1], *[1]University of Georgia, USA, [2]Artificial Cell Technologies Inc., USA, [3]Centers for Disease Control and Prevention, USA, [4]Emory Univeristy School of Medicine, USA*
[P2.57]	**Optimization of Linear Expression Cassette (LEC)-based DNA vaccines for enhanced transgene expression** H. Hedrick[1], A. Cox[1], M. Fons[1], D. Gregg[1], R. Heller[2], M. Zuber*[1], *[1]Vandalia Research, Inc., USA, [2]Old Dominion University, USA*
[P2.58]	**Induction of HPV specific CTLs in human volunteers after DNA immunization** M.P. Morrow*[1], J. Yan[1], A. Khan[1], D.B. Weiner[2], N.Y. Sardesai[1], M. Bagarazzi[1], *[1]Inovio Pharmaceuticals, USA, [2]The University of Pennsylvania, USA*
[P2.59]	**A public-professional web-bridge for vaccines and vaccination: User concerns about vaccine safety** A.L. García-Basteiro*[1], M.J. Alvarez-Pasquín[2], G. Mena[1], A. Llupià[1], M. Aldea[1], G. Sequera[1], S. Sanz[3], J. Tuells[4], J.A. Navarro-Alonso[5], J. De Arísteguí[6], J.M. Bayas[1], *[1]Preventative Medicine and Epidemiology Unit, Hospital Clínic, Spain, [2]Health Care Center Santa Hortensia, Spain, [3]CRESIB, Hospital Clínic-Universitat de Barcelona, Spain, [4]University of Alicante, Spain, [5]Regional Department of Health, Spain, [6]Hospital Universitario de Basurto, Spain*

Poster Session 3
Tuesday 4 October, 12:30 – 14:30

Production / Manufacturing / Safety	
[P3.1.1]	**Development of improved in vitro vaccine design system on the basis of enzymatic modification of HBc antigens with substituted C-terminal arginine residues** D. Zhulenkovs*, A. Leonchiks, *Latvian Biomedical Research and Study Center, Latvia*
[P3.1.2]	**Fermentation DOE study using scale-down model** H. Sun*, B. Pattara, M. Gao, P. Farrell, *Sanofi Pasteur, Canada*
[P3.1.4]	**Molecular imaging analysis of a nasal vaccine in mice and non-human primates** Y. Yuki*[1], T. Nochi[1], N. Harada[2], Y. Katakai[3], H. Tsukada[2], H. Kiyono[1], *[1]The University of Tokyo, Japan, [2]Hamamatsu Photonics K.K., Japan, [3]National Institute of Biomedical Innovation, Japan*
[P3.1.5]	**Viral removal validation from antivenom horse immunoglobulin** J.T. Yoshida[1], L.O. Nascimento[1], A.T.P. Caricati[1,2], C.P. Caricati[2], A. Pessoa Jr[1], M.A. Stephano*[1], *[1]São Paulo University, Brazil, [2]Butantan Institute, Brazil*
Regulatory / Societal / Legislation aspects	
[P3.2.1]	**Vaccine production training to develop the workforce of foreign institutions supported by the BARDA influenza vaccine capacity building program** B. Tarbet*, J. Dorward, C. Day, K. Rashid, *Utah State University, USA*
[P3.2.2]	**Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population** C.A. Castañeda-Orjuela*[1], N.R. Alvis-Guzman[2], A.J. Paternina[2], F. De la Hoz-Restrepo[1], *[1]Universidad Nacional de Colombia, Colombia, [2]Universidad de Cartagena, Colombia*
[P3.2.3]	**Cost-effectiveness of pneumococcal conjugates vaccines of 10 and 13 valences in Colombian children** C.A. Castañeda-Orjuela*[1], F. De la Hoz-Restrepo[1], N.R. Alvis-Guzman[2], *[1]Universidad Nacional de Colombia, Colombia, [2]Universidad de Cartagena, Colombia*
Vectors / Adjuvants / Drug delivery	
[P3.3.1]	**Role of TLR agonists in reducing RSV vaccine related enhanced respiratory disease** M.A. Sackal*[1], C.A. Shaw[1], K.E. Bowenkamp[2], S. Jain[1], K. Friedrich[1], T.M. Scalzo[1], *[1]Novartis Vaccines and Diagnostics, USA, [2]Novartis Institutes for Biomedical Research, USA*
[P3.3.2]	**CCL3 co-delivery by an adenovirus-based vaccine induces improved protection from retrovirus infection** R. Lietz[1], L. Johrden[1], M. Tenbusch[1], U. Dittmer[2], O. Wildner[3,1], W. Bayer*[2,1], *[1]Ruhr-University Bochum, Germany, [2]University Duisburg-Essen, Germany, [3]Paul-Ehrlich-Institute, Germany*

[P3.3.3]	**Stable assemblies of CpG oligonucleotide and cationic bilayer fragments with enhanced immunoadjuvant activity *in vivo*** J.H.K. Rozenfeld[1], S.R. Silva[2], P.A. Ranéia[2], E. Faquim-Mauro[2], A.M. Carmona-Ribeiro*[1], *[1]Universidade de São Paulo, Brazil, [2]Instituto Butantan, Brazil*
[P3.3.4]	**Increase of the adjuvant capability of Chiococca alba saponin by the increase of one sugar residue in the C-28 triterpene attached sugar chain. Effect on protection against visceral leishmaniasis** L.M. Brandão, R.M. Borges, D. Nico, A.J.R. Da Silva, M. Palatnik, C.B. Palatnik de Sousa*, *Universidade Federal do Rio de Janeiro, Brazil*
[P3.3.5]	**Soluble proteins induce strong CD8$^+$ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2** B. Chua*, D. Pejoski, S. Turner, W. Zeng, D. Jackson, *University of Melbourne, Australia*
[P3.3.6]	**Improvement of the immunity of piglets to PRRS vaccine by porcine IL-4 and IL-6 fusion gene encapsulated in chitosan nanoparticles** H. Zhang, R. Gao*, G. Bai, *Sichuan University, China*
[P3.3.7]	**Adjuvant potential of Vitamin A: Potentiation of TLR4 agonist activity and delivery in engineered probiotic bacteria** J.K. Miller, T. Harrison, A.K. Galande, A. D'Andrea, K. Kodukula, D.S. Watson*, *SRI International, USA*
[P3.3.8]	**Formulated TLR4 agonist induces CD8 T cell responses against malaria PfCSP** M. Moutaftsi*, G. Nana, J. Vergara, D. Carter, R. Coler, S. Reed, *Infectious Disease Research Institute, USA*
[P3.3.9]	**Cytokin adjuvant, recombinant chicken interleukin-18 (chIL-18) construct exhibits bioactivity** W.T. Chen*, S.Y. Chang, H.S. Yin, *National Tsing Hua University, Taiwan*
[P3.3.10]	**Adjuvant activity of chicken interleukin-12 co-administered with infectious bursal disease virus recombinant VP2 antigen in chickens** W.T. Chen*[1], L.H. Lee[2], H.S. Yin[1], *[1]National Tsing Hua University, Taiwan, [2]National Chung Hsing University, Taiwan*
[P3.3.11]	**Immune responses induced by pulmonary delivery of influenza ISCOMATRIX™ vaccine** J.P. Scheerlinck[1], *[1]The University of Melbourne, Australia, [2]CSL Limited, Australia*
[P3.3.12]	**Are we using the maximum achievable adjuvant effect of nanoparticlulate carriers?** B. Loretz*[1], C. Philippi[2], C. Thiele[1], M. Schnabel[3], G. Wenz[3], C.M. Lehr[1,2], *[1]Helmholtz-Institute for Pharmaceutical Research Saarland, Germany, [2]Biopharmaceutics and Pharmaceutical Technology, Saarland University, Germany, [3]Organic Macromolecular Chemistry, Saarland University, Germany*
[P3.3.13]	**Biodegradable nanoparticles induce innate and adaptive immunity via TLR4 signaling pathway** T. Uto*[1,4], T. Akagi[2,4], K. Yoshinaga[3,4], M. Toyama[1,4], Y. Nishi[1,4], M. Akashi[2,4], *[1]Kagoshima University, Japan, [2]Osaka University, Japan, [3]Kumamoto NCT, Japan, [4]JST-CREST, Japan*
[P3.3.14]	**High potency of novel polymeric adjuvant in eliciting the immune response in mice to major antigens of *Chlamydia* and *Yersinia*** V. Feodorova*[1], A. Lyapina[1,2], O. Ulianova[1,3], T. Polyanina[1], Y. Eliseev[2], V. Motin[4], *[1]Saratov State Veterinary Institute, Russia, [2]Saratov State Medical University, Russia, [3]Saratov State University, Russia, [4]University of Texas Medical Branch, USA*
[P3.3.15]	**Semi-conductor based nanotech vaccine carrier technology system in veterinary species** M.D. Welsh*[1], S.R. Saffie-Siebert[2], S. Doherty[1], N. Torabipour[2], *[1]AFBI, UK, [2]SiSaf Ltd, UK*
[P3.3.16]	**A broadly applicable stabilisation technology for vaccines and other complex biological molecules** J. Drew, *Stabilitech Ltd, UK*
[P3.3.17]	**Defining small molecule agonists of RIG-I-like receptor (RLR) signalling as novel vaccine adjuvants** Y.M. Loo*[1], M.K. Muramatsu[1], K. Bedard[2], M. Wang[2], S. Proll[1], R. Green[1], R.C. Ireton[1], M.G. Katze[1], S.P. Iadonato[2], M. Gale[1], *[1]University of Washington, USA, [2]KINETA, Inc., USA*
[P3.3.18]	**A paradigm shift for adjuvants: The matrix immune modulator** R.D. Ritchie*[1], A. Overby[1], M.A. Suckow[2,1], *[1]Bioscience Vaccines, Inc., USA, [2]The University of Notre Dame, USA*
[P3.3.19]	**Freeze-thaw stability of outer membrane model vaccines: Comparison of two different aluminum adjuvants** B. Hu, C. Mensch, C. Przysiecki, L. Zhang, P. Ahl*, *Merck Research Labs, USA*
Veterinary vaccines	
[P3.4.1]	**Improvement of live PRRS vaccines with Montanide™ Gel 01** S.D. Deville*[1], G.I. Ionkoff[1], F.B. Bertrand[1], S.K. Kukushkin[2], T.B. Baybikov[2], V.B. Borisov[2], *[1]SEPPIC, France, [2]FGI "ARRIAH", Russia*
[P3.4.2]	**Montanide™ Adjuvants for mucosal vaccination, application with live avian vaccines** S.D. Deville*[1], F.B. Bertrand[1], V.B. Borisov[2], L.D. Dupuis[1], *[1]SEPPIC, France, [2]FGI "ARRIAH", Russia*
[P3.4.3]	**Efficacy of a live vaccine against Porcine Epidemic Diarrhea (PED)** O.V. Sergeyev*, T.I. Aliper, *D. Ivanovski Institute of Virology, Russia*
[P3.4.4]	**Strategies of the process for the conservation of the potency of rabies vaccine for veterinary use by lyophilization** A.T.P. Caricati*[2,1], M.A. Stephano[1], C.P. Caricati[2], R.N.M. Pitombo[1], *[1]University of Sao Paulo, Brazil, [2]Butantan Institut, Brazil*

[P3.4.5]	**Does immunotherapy protect equines from the reinfection by the oomycete Pythium insidiosum?** R.A. Zanette*[1], C.E. Santos[2], P.A. Hecktheuer[1], N. Risso[1], L.C. Marques[2], J.M. Santurio[1], *[1]Universidade Federal de Santa Maria, Brazil, [2]Universidade Estadual Paulista, Brazil*
[P3.4.6]	**Brucella spp. Lumazine Synthase as a novel immunomodulator to produce egg yolk antibodies** D. Bellido[1], P. Chacana[1], M.V. Mozgovoj[1], D.D. Gonzalez[1], F.A. Goldbaum[2], A. Wigdorovitz[1], M.J. Dus Santos*[1], *[1]Instituto de Virología, INTA Castelar, Argentina, [2]Fundación Instituto Leloir, Argentina*
[P3.4.7]	**Efficacy of Chitosan and Montanide ISA 70 as an adjuvant to prepration of inactivated influenza vaccine** I. Khalili*[1], S. Avagian[2], B. Fathinajafi[2], *[1]RAZI VACCINE &SERUN INSTITUTE, Iran, [2]AGRERIAN STATE UNIVERSITY, Armenia*
[P3.4.8]	**Milk-derived antimicrobial peptides to protect against Neonatal Diarrheal Disease: An alternative to antibiotics** H.L. Wilson*, R.M. Buchanan, B. Allan, K.S. Tikoo, *University of Saskatchewan/VIDO-Intervac, Canada*
[P3.4.9]	**Development and evaluation of a vaccine stress reliever for pigs** B.H. Hyun*[1], J.J. Kim[1], S.I. Lim[1], C.H. Hong[2], P.H. Min[2], J.Y. Song[1], *[1]Animal Plant & Fisheries Quarantine & Inspection Agency, Republic of Korea, [2]SAMYANG ANIPHARM Co.,LTD, Republic of Korea*
[P3.4.10]	**Electron-beam irradiation inactivation of Salmonella: Effects on innate immunity and induction of protection against S*almonella enterica* serovar typhimurium challenge of chickens** M.H. Kogut*[1], P. Jesudhasan[2], A. Byrd[1], M. Davidson[2], H. He[1], S. Pillai[2], *[1]USDA-ARS, USA, [2]Texas A&M University, USA*
[P3.4.11]	**Utilization of Poly(I:C)-immunization for viral nervous necrosis in sevenband grouper** H.J. Gye*[1], I. Takami[2], M.J. Oh[1], T. Nishizawa[1], *[1]Chonnam National University, Republic of Korea, [2]Tsushima Fisheries Expansion Advisory Center, Japan*
[P3.4.12]	**Live vaccine of viral hemorrhagic septicemia virus (VHSV) for Japanese flounder at fish rearing temperature of 21°C instead of Poly(I:C) administration** M.J. Yang*[1], I. Takami[2], M.J. Oh[1], T. Nishizawa[1], *[1]Chonnam National University, Republic of Korea, [2]Tsushima Fisheries Expansion Advisory Center, Japan*
[P3.4.13]	**Vaccination of lactating dairy cows for the prevention of Aflatoxin B_1 carry over in the milk** L. Giovati*[1], W. Magliani[1], A. Gallo[2], F. Masoero[2], G. Piva[2], L. Polonelli[1], *[1]Università degli Studi di Parma, Italy, [2]Università Cattolica del Sacro Cuore di Piacenza, Italy*
[P3.4.14]	**Oral immunization of fish using recombinant major capsid protein with chitosan resin formulae** J.Y. Seo, J.I. Lee, T.J. Kim*, *Chonnam National University, Republic of Korea*
[P3.4.15]	**Vaccine potential of an attenuated Pasteurella multocida, which expresses only the N-terminal truncated fragment of P. multocida toxin in pigs** J.Y. Seo, C.H. Son, T.J. Kim*, *Chonnam National University, Republic of Korea*
[P3.4.16]	**Chicken egg yolk antibodies against bovine respiratory syncytial virus neutralize the virus *in vitro*** A. Ferella, D. Bellido, P. Chacana, A. Wigdorovitz, M.J. Dus Santos*, M.V. Mozgovoj, *Instituto Nacional de Tecnología Agropecuaria, Argentina*
[P3.4.17]	**Adenosine deaminase activity decreases in rabbit lymphocytes submitted to Pythium insidiosum immunotherapy** P.E.R. Bitencourt*, R.A. Zanette, S.H. Alves, J.M. Santurio, M.B. Moretto, M.B. Pilotto, *Universidade Federal de Santa Maria, Brazil*
[P3.4.18]	**Immune gene expression of olive flounder against viral hemorrhagic septicemia virus vaccine/combination with several adjuvant** S.J. Jung*, V. Tharabenahalli Nagaraju, C.S. Park, S. Avunje, M.J. Oh, *Chonnam National University, Republic of Korea*
[P3.4.19]	**Rationale for the improvement of the DNA vaccine pCI-neo-LACK against canine leishmaniasis** A. Alonso*, P.J. Alcolea, V. Larraga, *Centro de Investigaciones Biológicas (Consejo Superior de Investigaciones Científicas), Spain*
[P3.4.20]	**Evaluation of the immune response induced by a bovine rotavirus subunit vaccine using two experimental models** D.D. Gonzalez, M.S. Perez Aguirreburualde, M.V. Mozgovoj, D. Bellido, V.G. Parreño, A. Wigdorovitz, M.J.D. Santos*, *Instituto de Virología, CICVyA, INTA, Argentina*
[P3.4.21]	**Oral administration of the recombinant *Lactococcus lactis* expressing C-terminal fragment of *Pasteurella multocida* toxin** A. Kim, H.J. Woo, J. Lee*, *Seoul National University, Republic of Korea*
[P3.4.22]	**The maintenance of intermolecular relationships within an immunogen enhances antibody production but not protective immunity** S. Noh*[1,2], J. Turse[2], W. Brown[2], G. Palmer[2], *[1]USDA-Agriculture Research Service, USA, [2]Washington State University, USA*
[P3.4.23]	**Targeted transcriptome analysis of commercial live attenuated bivalent Marek's disease vaccine administered in ovo in chicken** S.N.N.V. Neerukonda*, M.S. Parcells, S.P. Golovan, *University of Delaware, USA*
[P3.4.24]	**Recombinant baculovirus expressing envelope glycoprotein E of the local BoHV-1** E.R. Abdo[1], A.A. El Kholy[1], H.A. Hussein*[2], *[1]Serum and Vaccine Research Institue, Egypt, [2]CAiro University, Egypt*

[P3.4.25]	**Characterization of culture supernatant proteins from Brucella abortus and its protection effects against murine brucellosis** J.J. Lim, D.H. Kim, J.J. Lee, D.G. Kim, S. Kim*, *Gyeongsang National University, Republic of Korea*
[P3.4.26]	**Immune responses to a polymeric (PLGA) nanoparticle vaccine carrier technology in cattle** S. Doherty[1], F. Mansoor[1], B. Earley[2], J.P. Cassidy[3], B. Markey[3], M.D. Welsh*[1], *[1]Agri-Food & Biosciences Institute, UK, [2]Teagasc, Ireland, [3]University College Dublin, Ireland*
[P3.4.27]	**Pre-exposure of Canada geese to low pathogenic avian influenza H1N1 virus protects against lethal H5N1 infection** Y. Berhane*, J. Neufield, H. Kehler, M. Leith, M. Suderman, J. Pasick, *National Center For Foreign Animal Disease, Canada*
[P3.4.28]	**A multiepitope DNA vaccine against FMD expressing Bcl-xL anti-apoptotic protein enhances $CD8^+$ IFN-gamma responses** S. Gulce Iz*[1], M. Doskaya[2], B. Borrego[3], F. Rodriguez[4], A.Y. Guruz[2], S.I. Deliloglu Gurhan[1], *[1]Ege University, Bioeng. Dept., Turkey, [2]Ege University, Medical School, Dept of Parasitology, Turkey, [3]CISA-INIA, Spain, [4]CReSA, Spain*
[P3.4.29]	**Immunity against antigens selected from a transcriptome of tick salivary glands presenting expressed genes affected by resistant hosts diminishes reproductive efficiency of ticks** S.R. Maruyama*[1], E. Anatriello[1], I.K.F. De Miranda Santos[1], C. Veríssimo[2], J. Valenzuela[3], B.R. Ferreira[4], *[1]Ribeirão Preto School of Medicine, University of São Paulo, Brazil, [2]São Paulo Institute of Animal Science, Brazil, [3]National Institute of Allergy and Infectious Disease, USA, [4]Ribeirão Preto School of Nursing, University of São Paulo, Brazil*
[P3.4.30]	**Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines** S.C. Lin[1], M. H. Huang[2], P.C. Tsou[1], L.M. Huang[3], P. Chong[2], S.C. Wu[1,2]*, *[1] National Tsing Hua University, Taiwan, [2] National Health Research Institutes, Taiwan, [3] National Taiwan University Hospital, Taiwan*
[P3.4.31]	**Dengue type 4 live-attenuated vaccine viruses passaged in Vero cells affect genetic stability and dengue-induced hemorrhaging in mice** H. C. Lee[1], B. A. Wu-Hsieh [3], Y. T. Yen [3], S. C. Wu[1,2]*, *[1]Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan, [2]National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Taiwan, [3]Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taiwan*